A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when administered to healthy subjects seven years of age and older - MMR-159

GlaxoSmithKline Biologicals0 个研究点目标入组 1,000 人开始时间: 2015年1月20日最近更新: 2015年12月7日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: GlaxoSmithKline Biologicals
入组人数: 1,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects who the investigator believes that they and/or their parent(s) or Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
•Male or female subjects 7 years of age or older and born after December 31, 1956*. *The only exception to this is health care workers born before 1957 without other evidence of immunity to mumps for which one dose of a live mumps virus vaccine is recommended; therefore this population is eligible for enrollment in this study.
•For all children 7-17 years of age:
•-Written documentation of prior receipt of 1 dose of MMR vaccine administered on or after the first birthday.
•For all adults 18 years of age and older:
•-Prior receipt (written or verbal history) of at least one dose of MMR vaccine.
•-Birth in the US.
•Written informed consent obtained from the subject or from the parent(s)/LAR(s) of the subject (assent will be obtained from subjects who are still legally minors in line with local rules and regulations).
•Subjects in stable health as determined by investigator’s physical examination and assessment of subjects’ medical history.
•Female subjects of non-childbearing potential may be enrolled in the study.
•-Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, or ovariectomy or post-menopause.
•Female subjects of childbearing potential may be enrolled in the study, if the subject
•-Has agreed to be abstinent or practiced adequate contraception during the entire period starting 30 days prior to vaccination(s) until 3 months after receipt of the study vaccination and
•-Has a negative pregnancy test on the day of vaccination.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 334
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 666
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Child in care.
•For all children 7-17 years of age:
•-Previous receipt of more than 1 dose of a measles-containing vaccine.
•Use of any investigational or non-registered product other than the study vaccine(s), during the period starting 30 days preceding the day of study vaccination, (i.e. 30 days prior to Day 0) or planned use during the entire study period.
•Receipt of any measles, mumps or rubella-containing vaccine during the period starting 42 days before the day of study vaccination (i.e. 42 days prior to Day 0).
•Chronic administration (defined as 14 or more consecutive days) of immunosuppressants or other immune-modifying drugs during the period starting 180 days before study vaccination or any planned administration of immune-modifying drugs during the entire study. Inhaled and topical steroids are allowed.
•Administration of immunoglobulins and/or any blood products during the period starting 180 days prior to study vaccination through the immunogenicity evaluation at Visit 2 or Visit 3 (for one-dose or two-dose cohort, respectively).
•Planned administration/ administration of any live viral vaccine not foreseen by the study protocol during the period starting 30 days prior to study vaccination and ending at Visit 2. Any inactivated vaccine required in the age group and inactivated influenza vaccine may be given at any time, including the day of study vaccination. (Inactivated vaccines must be administered at a different location than the study vaccine). Live intranasal influenza vaccine should not be given during the period starting 30 days prior to study vaccination and ending at Visit 2, except for the day of study vaccination.
•Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
•History of measles, mumps, or rubella disease.
•Known exposure to measles, mumps, or rubella, during the period starting 30 days before study start (i.e. 30 days prior to Day 0).
•Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
•History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including hypersensitivity to neomycin, latex or gelatin.
•Blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms.
•Acute disease at the time of enrollment.
•Alcohol or drug abuse or history of any substance abuse.
•Pregnant or lactating female.
•Female planning to become pregnant or planning to discontinue contraceptive precautions during the entire study period.
•Active untreated tuberculosis according to the subject’s medical history
•Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.

研究者

发起方

GlaxoSmithKline Biologicals

相似试验

进行中（未招募）

不适用

EUCTR2011-004638-32-Outside-EU/EEAGlaxoSmithKline Biologicals4,000

进行中（未招募）

不适用

Immunogenicity and safety study of GSK Biologicals´ combined measles-mumps-rubella vaccine in subjects seven years of age and older (209762).

EUCTR2011-003672-36-SKGlaxoSmithKline Biologicals S.A.1,000

进行中（未招募）

不适用

A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A as compared to the Dresden-manufactured A/California/7/2009 (H1N1)v-like antigen adjuvanted with AS03A. - FLU D-PAN H1N1-017Immunization against A/California/7/2009 (H1N1)v-like influenza in male and female subjects aged 18 to 60 years.

EUCTR2009-014419-11-DEGlaxoSmithKline Biologicals320

进行中（未招募）

1 期

EUCTR2009-014419-11-FRGlaxoSmithKline Biologicals320

进行中（未招募）

不适用

A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children during the second year of life following a 4-week and a 12-month interval between two doses - MMRV-042 & MMRV-045Active immunization of healthy children during their second year of life against measles, mumps, rubella and varicella diseases.

EUCTR2004-004371-11-DEGlaxoSmithKline Biologicals540